1
Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug
Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in-
development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic
interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain
health, as well as for age-related health concerns that can affect brain health (e.g.,
cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports
include evaluation of safety data, from clinical trials if available, and from preclinical models.
Piracetam Evidence Summary
Piracetam benefits cognitive functions in older adults, though many of the studies are old and the
quality suboptimal. It does interact with anticoagulants and thyroid extracts.
Neuroprotective Benefit: Several studies have shown that piracetam benefits cognitive
functions in older individuals but not in dementia patients. Despite the numerous clinical trials,
many are old and did not use sophisticated measures.
Aging and related health concerns: No studies have tested whether piracetam prevents age-
related diseases, though piracetam intervention pre- and post-surgery reduced postoperative
cognitive decline in heart surgery patients.
Safety: Piracetam is well tolerated, but it does interact with anticoagulants and thyroid
extracts and people with suspected kidney problems or bleeding problems should talk to their
doctor before taking piracetam.
2
Availability: Not OTC Dose: 1,200-4,800 mg per day in
adults
Chemical formula: C6H10N2O2
MW: 142.158
Source: PubChem
Half life: 5 hours in young
adult men
BBB: penetrant
Clinical trials: Largest meta-
analysis included 24 DBRCTs
including a total of 11,959
subjects (half of whom
received placebo)
Observational studies: none
What is it? Piracetam is a nootropic and the parent compound of the racetam drug class. It was first
marketed by UCB Pharma in Belgium in 1971, but in the US, it is not approved for any medical use and it
is not permitted to be sold as a dietary supplement (DrugBank). In the UK, piracetam is prescribed for
myoclonus (involuntary spasmodic contraction of muscles), but it is used off-label for learning difficulties
in children and cognitive deficits in the elderly. Piracetam modulates the cholinergic, serotonergic,
noradrenergic, and glutamatergic neurotransmission (DrugBank). It does not have high affinity to any of
the neurotransmitter receptors, but it does bind to the glutamate receptor subunit GluA2 [1]. Piracetam
interacts with the polar heads of phospholipids making up the plasma membrane and influences
membrane function and fluidity.
Neuroprotective Benefit: Several studies have shown that piracetam benefits cognitive functions in
older individuals but not in dementia patients. Despite the numerous clinical trials, many are old and did
not use sophisticated measures.
Types of evidence:
• 8 meta-analyses in various patient populations
• 8 randomized controlled clinical trials
• 1 PET imaging study in dementia patients
• Numerous laboratory studies
3
Human research to suggest prevention of dementia, prevention of decline, or improved cognitive
function?
Aged individuals: POTENTIAL BENEFIT. Many of the clinical trials are from the 70’s and 80’s and some of
the outcome measures were subjective. In a double-blind controlled crossover study of 18 normally
aged individuals, piracetam treatment (1.6 g x 3 times daily) for 4 weeks was associated with
significantly better performance on the Digit Symbol Test, Bourdon-Wiersma Test (visual perception),
Spoke Test (similar to trail making test), Critical Flicker Fusion (visual function), and Krakau Visual Acuity
Test [2]. In a larger double-blind controlled trial of 50 geriatric patients, piracetam treatment (2.4 g/day)
did not show statistically significant differences compared to controls in 10 different cognitive tests.
However, on Clinical Global Evaluation, 52% of the patients on piracetam showed minimal improvement
versus 25% of the patients in the placebo group [3].
Cognitively impaired older adults: BENEFIT. In a 2002 meta-analysis of 19 double-blind randomized
controlled trials including a total of 1,489 older adults with cognitive impairment, piracetam treatment
(2.4-8.0 g/day; duration ranged from 6 weeks to 52 weeks, mostly 6-12 weeks) was associated with
improvement in clinical assessment [4]. The comparison was "piracetam better" vs "placebo better" and
the magnitude of change could not be measured as most studies (12/19) used Clinical Global Impression
(a 7-point scale) as their sole outcome; only 7 studies also used psychometric assessments. In the
placebo arm, 227 improved (34.1%) and 438 (65.9%) experienced no change or got worse. In the
piracetam arm, 481 improved (63.9%) while 272 (36.1%) showed no change or got worse.
In a double-blind controlled study (not included in the above meta-analysis) in 60 elderly psychiatric
patients with mild cerebral impairment, piracetam treatment for 12 weeks improved overall functioning,
particularly alertness, socialization, and cooperation, relative to the control group [5]. Patients treated
with 2.4 g/day piracetam showed significant improvement in scores for the full IQ and the memory
quotient on the Wechsler Adult Intelligence and Memory Scales; greater response was seen in those
with lower initial scores. Piracetam at 4.8 g/day had a more rapid onset of action on behavioral variables
than 2.4 g/day, but its therapeutic effect tended to diminish at 12 weeks, possibly because of
overstimulation. Piracetam did not appear to interfere with concomitant psychotropic maintenance
medication or affect the psychiatric illness itself.
Vascular cognitive impairment: UNKNOWN. Based on a 2017 review on vascular cognitive impairment,
benefits of piracetam are not clear [6]. There have not been any well-designed studies that have
demonstrated convincing evidence to support routine use of piracetam.
4
Stroke patients: SOME BENEFIT. In a meta-analysis of 7 randomized controlled trials in post-stroke
patients, piracetam treatment (mostly 4.8 g/day; duration ranged from 2 weeks to 6 months) did not
improve overall severity of aphasia, but the treatment was associated with pronounced improvement in
written language [7]. The study also noted that piracetam’s effects on overall linguistic level and written
language tended to emerge within a short period and declined in longer therapy.
TBI patients: UNKNOWN. In a meta-analysis of clinical or observational studies in patients with
traumatic brain injury that examined various therapeutics (e.g., cerebrolysin, citicoline, piracetam),
there was not enough available research to gauge the effects of piracetam in TBI management [8].
Children: MIXED. In a meta-analysis and clinical practice guideline for children with reading or spelling
disorders in children and adolescents, they recommended against the use of piracetam [9]. In a
randomized controlled trial of 250 children undergoing general anesthesia, intravenous piracetam (30
mg/kg) prevented postoperative cognitive dysfunction, though the full text was not accessible so the
extent of cognitive improvement/preservation could not be evaluated [10].
Human research to suggest benefits to patients with dementia:
Alzheimer’s dementia: LACK OF BENEFIT. In a double-blind randomized controlled trial of 33 probable
Alzheimer’s patients, high dose piracetam (8 g/day, orally) for 1 year did not result in improvement in
cognitive functions [11]. The full text for this study was not accessible so the results could not be fully
evaluated.
In a small double-blind crossover trial of 18 Alzheimer’s patients, piracetam treatment (2.4-9.9 g/day),
either alone or in combination with phosphatidylcholine (18 g/day), did not significantly affect cognition
as a whole, nor did it improve test performance in any single patient [12]. The link to the full text for this
study was broken so details could not be evaluated.
In an even smaller double-blind crossover trial of 11 Alzheimer’s patients, piracetam (4.8 g/day) +
lecithin (35 g/day) treatment for 3 months showed that 8 out of 11 patients showed various degrees of
improvement compared to the placebo phase [13]. The remaining patients did not improve or worsened
during the active phase. Piracetam plus lecithin may ameliorate selective memory deficits in some
patients. Nonresponders had little or no aphasia.
5
Parkinson’s/Lewy body dementia: LACK OF BENEFIT. In a meta-analysis of 44 different studies in Lewy
Body Dementia, only 1 tested the effect of piracetam [14]. It was a double-blind randomized controlled
trial of 20 people with Parkinson’s dementia, and patients were treated with piracetam (3.2 g/day for 12
weeks followed by 4.8 g/day for an additional 12 weeks) or placebo [15]. Twenty-five percent of the
patients did not complete the trial for reasons unrelated to the medication. Although there was a
significant improvement on one subtest (functional capacity measured by the Sickness Impact Profile) of
the functional scale, no significant effects were demonstrated in cognitive or neurological measures.
There is no evidence that piracetam changes any motor or cognitive aspect of Parkinson’s.
Nonspecific/unclassified dementias: MIXED. In a 2001 Cochrane meta-analysis of 24 double-blind
randomized controlled trials with a total of 11,959 subjects total, no significant differences were found
between piracetam treatment (2.4-9.6 g/day; duration ranged from 1 week to 1 year) and placebo
groups for cognition (immediate memory, visuospatial, Mini Mental Status Examination [MMSE],
delayed memory or speech), for dependency, or for depression [16]. Though using a fixed-effect model,
the odds ratio for improvement with piracetam compared with placebo was 3.55 (95% CI, 2.45 to 5.16).
Although effects were found on Global Impression of Change, no benefit was shown by any of the more
specific measures of cognitive function. Further evaluation of piracetam is needed. Piracetam was one
of the first drugs used for dementia and comes from the class of drugs called nootropics, whose putative
actions are still poorly defined. Most of the trials of piracetam were undertaken many years ago and did
not use methods which would be currently considered standard. Some of the studies suggested there
may be some benefit from piracetam but overall the evidence is not consistent or positive enough to
support its use for dementia or cognitive impairment. The mean difference for MMSE (1 study, 30
subjects) was 1.8 (-3.29 to 6.89). The mean difference for Global Scale was 0.27 (-0.62 to 1.17).
In a phase III double-blind randomized controlled trial in 130 patients with dementia (for at least 2
years), piracetam treatment (4.8 g/day) for 3 months showed statistically significant “explorative
response rates” of 50% and above in 3 out of 4 target variables (e.g., Clinical Global Impression, Sandoz
Clinical Assessment Geriatric, etc.) as compared to the 0-6% obtained with placebo [17]. The full text
was not accessible for this paper.
Mechanisms of action for neuroprotection identified from laboratory and clinical research:
A PET imaging study in 9 Alzheimer’s and 7 unclassified dementia patients reported that piracetam
treatment (6 g, twice daily) for 2 weeks significantly improved cerebral glucose metabolism in most
cortical areas (frontal, central, parietooccipital, visual, auditory, and cingulate cortex) in Alzheimer’s
6
patients, whereas no effect was observed in the multi-infarct dementia/unclassified dementia groups
[18]. The results suggest that the typical metabolic depression in Alzheimer's disease is caused by
complex interactions of disturbed transmitter and cellular function rather than by a specific deficit in the
cholinergic system alone. While the results were positive, it was a small study and the data are
preliminary.
In rodents, piracetam treatment prevented memory impairment induced by scopolamine [19] and
reversed inflammation (LPS)-induced spatial memory impairment [20]. These studies also showed that
piracetam decreased oxidative stress (lipid peroxidation, nitrite levels), prevented the increase in
neuroinflammation (IL6), and increased blood levels of Aβ suggesting greater efflux of Aβ from the brain
to the blood [20].
The mechanism of action for piracetam is that it enhances the fluidity of plasma membranes by
interacting with the polar heads of phospholipids. Piracetam also increases fluidity of brain
mitochondrial membranes and several studies have shown that piracetam enhances mitochondrial
membrane function, ATP production, and reduces sensitivity to apoptosis [21]. In cell culture systems,
piracetam also inhibited the opening of the mitochondrial permeability transition pore, which forms
under mitochondrial stress and can lead to mitochondrial swelling and apoptosis [22]. In rats injected
with rotenone (pesticide that interferes with the electron transport chain in mitochondria),
pretreatment with piracetam significantly protected against oxidative stress, though this benefit was not
seen when piracetam was given at the same time as rotenone [23].
In model plasma membranes, piracetam significantly decreased the harmful destabilizing effect of Aβ by
coating the phospholipid headgroups [24].
APOE4 interactions: No studies have examined the effects of piracetam based on APOE status.
Aging and related health concerns: No studies have tested whether piracetam prevents age-related
diseases, though piracetam intervention pre- and post-surgery reduced postoperative cognitive decline
in heart surgery patients.
Types of evidence:
• 3 meta-analyses, 2 in stroke patients and 1 in heart surgery patients
• Several laboratory studies
7
Stroke: LACK OF BENEFIT. No studies have examined whether piracetam may prevent stroke, but
several clinical trials have tested piracetam in people who have already experienced stroke. A meta-
analysis of randomized controlled trials (RCTs) in stroke patients reported that there is insufficient
evidence for the use of piracetam (3 RCTs) in promoting recovery from stroke [25].
In a 2012 Cochrane meta-analysis of 3 RCTs in acute ischemic stroke, piracetam was associated with a
non-significant increase in death at one month (approximately 31% increase, 95% CI, -5% to 81%) [26].
There were 1,002 patients total in this meta-analysis, but 1 trial contributed to 93% of the data. The
trend for increased death was no longer apparent in this large trial after correction for imbalance in
stroke severity. Limited data showed no differences between the treatment and control groups for
functional outcome, dependence, or proportion of patients who were dead/dependent. Although there
was a suggestion of an unfavorable effect of piracetam on early death, this was confounded by baseline
differences in stroke severity in the trials.
Cardiovascular: POTENTIAL BENEFIT. No studies have tested whether piracetam may prevent
cardiovascular disease, but a few randomized controlled trials (RCTs) have tested piracetam in patients
who underwent coronary bypass surgery. A meta-analysis of 3 RCTs including 282 patients undergoing
coronary bypass surgery evaluated the potential benefits of high dose piracetam treatments pre- and
post-surgery. For the 2 acute studies, piracetam infusion (12 g/60 ml, i.v.) prior to surgical intervention
provided short-term neuroprotective effect and reduced postoperative decline of neuropsychological
abilities [27]. For the third study, patients were administered 150 mg/kg i.v. piracetam prior to coronary
artery bypass grafting, followed by 12 g/day oral treatment for 6 weeks. After 6 weeks of treatment,
cognition was significantly improved in patients treated with piracetam compared to placebo. A
statistically significant difference was identified between the piracetam and control groups in the
change from baseline in 5 of the subtest scores (immediate pictured object recall, WMD=0.91, 95% CI,
0.51‑1.31; delayed pictured object recall, WMD=0.74, 95% CI, 0.19‑1.28; delayed picture recognition,
WMD=0.82, 95% CI, 0.31‑1.31; immediate word recall, WMD=0.87, 95% CI, 0.47‑1.28; letter
interference, WMD=-3.46, 95% CI, -5.69 to -1.23). No statistically significant difference was observed
between piracetam and control in attention scores.
Peripheral neuropathy: POTENTIAL BENEFIT IN PRECLINICAL STUDIES. No studies have tested piracetam
in people with peripheral neuropathy. In a rat model of peripheral neuropathic pain (by chronic
constriction injury of the sciatic nerve), piracetam treatment dose-dependently improved neuropathic
pain [28]. At 50 mg/kg, there were no effects, while at 100 mg/kg, rats had significantly decreased paw
withdrawal duration (cold allodynia test) while no effects were seen on the hot plate and tail flick tests
8
(thermal hyperalgesia tests). Piracetam at a dose of 200 mg/kg significantly modulated neuropathic
pain, based on increased hot plate and tail flick latencies, as well as decreased paw withdrawal duration.
The human equivalent dose for the highest dose was 32.3 mg/kg.
Safety: Piracetam is well tolerated, but it does interact with anticoagulants and thyroid extracts and
people with suspected kidney problems or bleeding problems should talk to their doctor before taking
piracetam.
Types of evidence:
• 2 Cochrane meta-analyses, 1 in acute ischemic stroke and 1 in painful sickle cell disease crises
• 2 double-blind clinical trials, 1 in Alzheimer’s patients and 1 in aged individuals
• 1 open-label trial in epilepsy patients
• 1 review
Clinical studies: Piracetam appears to be well-tolerated and very few studies reported toxic side effects,
though it is possible that because some of the studies were old and of suboptimal quality, there was
underreporting of adverse events.
In a 2016 Cochrane meta-analysis of 3 randomized controlled trials (RCTs) including 169 patients with
painful sickle cell disease crises, i.v. infusion of piracetam (doses ranged, but during crises, 160-300
mg/kg/day) did not result in toxicity or adverse effects other than one participant who experienced
dizziness [29].
A 2012 Cochrane meta-analysis of 3 RCTs including 1,002 patients with acute ischemic stroke stated that
adverse effects were not reported [26].
In two double-blind controlled studies, each including 18 patients, no side effects or toxic effects were
noted [2; 12]. In an open-label study of 11 subjects with progressive myoclonus epilepsy, 2 patients
reported drowsiness during the first 2 weeks of piracetam treatment, though there was no relationship
between the dosage and occurrence of adverse effects and none of the patients needed to discontinue
treatment [30]. When starting at a low dose (3.2 g/day) and increasing gradually (max dose 20 g/day),
none of the patients developed diarrhea, a common adverse effect of piracetam when given at a high
dosage.
9
The most comprehensive information was found in a 1999 review of post-marketing surveillance reports
in stroke patients [31]. The authors reviewed studies that included a total of 927 patients (464 treated
with piracetam) and confirmed piracetam’s safety profile and lack of organ toxicity across its 25 years of
clinical usage. Tolerance was equally high with the more recent use of larger doses (up to 24 g/day) for
the long-term control of cortical myoclonus and when given intravenously to patients with acute stroke.
Although death within 12 weeks occurred more often in the piracetam group (23.9%; 111/464) as
compared with placebo (19.2%; 89/463), the difference was not significant after controlling for initial
stroke assessment scale scores (Orgogozo scores). Factors other than treatment (piracetam) significantly
contributed to death, such as severity of stroke, age, female sex, myocardial infarction, and diabetes.
The adverse event profile was similar in both treatment and placebo groups, with no significant
differences in the numbers of patients with adverse events, frequency of adverse events overall, or
those considered serious. The types of adverse events also did not differ between groups. Nine
piracetam-treated and 6 placebo-treated patients discontinued treatment because of adverse events, all
considered unrelated or unlikely due to study medication. Seizures were reported in 5 piracetam-
treated and 16 placebo-treated subjects.
Treato rating: Treato.com rates piracetam 4.0 stars out of 5, with 3,998 positive comments compared
to 2,656 negative ones as of 4/2/2018. Side effects and concerns raised included sleepiness (524),
weakness (433), hypomania (219), paranoia (191), and weight gain (160).
Drug interactions: Based on leaflets for Nootropil®, piracetam may interact with thyroid extract,
thyroxine, anticoagulants (e.g., warfarin or acenocoumarol), and aspirin (Drugs.com). You should not
take piracetam if you have ever had serious kidney problems, brain hemorrhage, or if you suffer from
Huntington’s disease. People with suspected kidney problems or bleeding problems should talk to their
doctor or pharmacist before taking piracetam. Piracetam is excreted in human breast milk so should not
be taken by breastfeeding mothers (PubChem).
Sources and dosing: Piracetam is not sold OTC. Most clinical trials have used doses of 4.8 g/day (ranging
from 2.4-9.6 g/day) [4; 7; 13; 16; 17].
Research underway: No clinical trials are currently testing piracetam. A study to evaluate the efficacy
and safety of piracetam on aphasia after acute ischemic cerebral artery stroke was terminated after a
pre-specified interim analysis (NCT01883011). There are currently 19 ongoing clinical trials testing the
effects of levetiracetam, an antiepileptic drug with structural similarities to piracetam. A phase 2 trial
10
testing levetiracetam for Alzheimer’s disease is scheduled to be completed in December 2019
(NCT02002819).
Search terms:
Pubmed, Google: piracetam
• + cognitive, + Alzheimer’s, + ApoE, + meta-analysis, + clinical trial, + cardiovascular, +
inflammation, + lifespan, + safety, + toxicity
Websites visited for piracetam:
• Clinicaltrials.gov
• Examine.com
• Treato.com
• DrugAge (0)
• Geroprotectors (0)
• Drugs.com
• WebMD.com (no info)
• PubChem
• DrugBank.ca
• Labdoor.com (0)
• ConsumerLab.com (0)
References:
1. Ahmed AH, Oswald RE (2010) Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. J Med Chem 53, 2197-2203.https://www.ncbi.nlm.nih.gov/pubmed/20163115
2. Mindus P, Cronholm B, Levander SE et al. (1976) Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals. Acta Psychiatr Scand 54, 150-160.https://www.ncbi.nlm.nih.gov/pubmed/785952
3. Abuzzahab FS, Sr., Merwin GE, Zimmermann RL et al. (1977) A double blind investigation of piracetam (Nootropil) vs placebo in geriatric memory. Pharmakopsychiatr Neuropsychopharmakol 10, 49-56.https://www.ncbi.nlm.nih.gov/pubmed/360232
4. Waegemans T, Wilsher CR, Danniau A et al. (2002) Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord 13, 217-224.https://www.ncbi.nlm.nih.gov/pubmed/12006732
5. Chouinard G, Annable L, Ross-Chouinard A et al. (1983) Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacology (Berl) 81, 100-106.https://www.ncbi.nlm.nih.gov/pubmed/6415738
11
6. Farooq MU, Min J, Goshgarian C et al. (2017) Pharmacotherapy for Vascular Cognitive Impairment. CNS Drugs 31, 759-776.https://www.ncbi.nlm.nih.gov/pubmed/28786085
7. Zhang J, Wei R, Chen Z et al. (2016) Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. CNS Drugs 30, 575-587.https://www.ncbi.nlm.nih.gov/pubmed/27236454
8. El Sayed I, Zaki A, Fayed AM et al. (2018) A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurg Rev 41, 427-438.https://www.ncbi.nlm.nih.gov/pubmed/27539610
9. Galuschka K, Schulte-Korne G (2016) The Diagnosis and Treatment of Reading and/or Spelling Disorders in Children and Adolescents. Dtsch Arztebl Int 113, 279-286.https://www.ncbi.nlm.nih.gov/pubmed/27159142
10. Fesenko UA (2009) Piracetam improves children's memory after general anaesthesia. Anestezjol Intens Ter 41, 16-21.https://www.ncbi.nlm.nih.gov/pubmed/19517672
11. Croisile B, Trillet M, Fondarai J et al. (1993) Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 43, 301-305.https://www.ncbi.nlm.nih.gov/pubmed/8437693
12. Growdon JH, Corkin S, Huff FJ et al. (1986) Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 7, 269-276.https://www.ncbi.nlm.nih.gov/pubmed/3528889
13. Samorajski T, Vroulis GA, Smith RC (1985) Piracetam plus lecithin trials in senile dementia of the Alzheimer type. Ann N Y Acad Sci 444, 478-481.https://www.ncbi.nlm.nih.gov/pubmed/3893273
14. Stinton C, McKeith I, Taylor JP et al. (2015) Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry 172, 731-742.https://www.ncbi.nlm.nih.gov/pubmed/26085043
15. Sano M, Stern Y, Marder K et al. (1990) A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease. Mov Disord 5, 230-234.https://www.ncbi.nlm.nih.gov/pubmed/2388639
16. Flicker L, Grimley Evans G (2001) Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev, CD001011.https://www.ncbi.nlm.nih.gov/pubmed/11405971
17. Herrmann WM, Stephan K (1992) Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam. Int Psychogeriatr 4, 25-44.https://www.ncbi.nlm.nih.gov/pubmed/1391670
18. Heiss WD, Hebold I, Klinkhammer P et al. (1988) Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J Cereb Blood Flow Metab 8, 613-617.https://www.ncbi.nlm.nih.gov/pubmed/3260597
19. Marisco PC, Carvalho FB, Rosa MM et al. (2013) Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5'-nucleotidase and adenosine deaminase activities. Neurochem Res 38, 1704-1714.https://www.ncbi.nlm.nih.gov/pubmed/23677777
20. Tripathi A, Paliwal P, Krishnamurthy S (2017) Piracetam Attenuates LPS-Induced Neuroinflammation and Cognitive Impairment in Rats. Cell Mol Neurobiol 37, 1373-1386.https://www.ncbi.nlm.nih.gov/pubmed/28176051
12
21. Leuner K, Kurz C, Guidetti G et al. (2010) Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam. Front Neurosci 4.https://www.ncbi.nlm.nih.gov/pubmed/20877425
22. Stockburger C, Miano D, Pallas T et al. (2016) Enhanced Neuroplasticity by the Metabolic Enhancer Piracetam Associated with Improved Mitochondrial Dynamics and Altered Permeability Transition Pore Function. Neural Plast 2016, 8075903.https://www.ncbi.nlm.nih.gov/pubmed/27747106
23. Verma DK, Joshi N, Raju KS et al. (2015) Metabolic enhancer piracetam attenuates rotenone induced oxidative stress: a study in different rat brain regions. Acta Neurobiol Exp (Wars) 75, 399-411.https://www.ncbi.nlm.nih.gov/pubmed/26994419
24. Mingeot-Leclercq MP, Lins L, Bensliman M et al. (2003) Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Abeta C-terminal fragment. Biochim Biophys Acta 1609, 28-38.https://www.ncbi.nlm.nih.gov/pubmed/12507755
25. Yeo SH, Lim ZI, Mao J et al. (2017) Effects of Central Nervous System Drugs on Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig 37, 901-928.https://www.ncbi.nlm.nih.gov/pubmed/28756557
26. Ricci S, Celani MG, Cantisani TA et al. (2012) Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev, CD000419.https://www.ncbi.nlm.nih.gov/pubmed/22972044
27. Fang Y, Qiu Z, Hu W et al. (2014) Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: A meta-analysis. Exp Ther Med 7, 429-434.https://www.ncbi.nlm.nih.gov/pubmed/24396419
28. Mehta AK, Bhati Y, Tripathi CD et al. (2014) Analgesic effect of piracetam on peripheral neuropathic pain induced by chronic constriction injury of sciatic nerve in rats. Neurochem Res 39, 1433-1439.https://www.ncbi.nlm.nih.gov/pubmed/24831122
29. Al Hajeri A, Fedorowicz Z (2016) Piracetam for reducing the incidence of painful sickle cell disease crises. Cochrane Database Syst Rev 2, CD006111.https://www.ncbi.nlm.nih.gov/pubmed/26869149
30. Fedi M, Reutens D, Dubeau F et al. (2001) Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 58, 781-786.https://www.ncbi.nlm.nih.gov/pubmed/11346373
31. De Reuck J, Van Vleymen B (1999) The clinical safety of high-dose piracetam--its use in the treatment of acute stroke. Pharmacopsychiatry 32 Suppl 1, 33-37.https://www.ncbi.nlm.nih.gov/pubmed/10338106
13
Disclaimer: Cognitive Vitality Reports® do not provide, and should not be used for, medical
advice, diagnosis, or treatment. You should consult with your healthcare providers when
making decisions regarding your health. Your use of these reports constitutes your agreement
to the Terms & Conditions.
If you have suggestions for drugs, drugs-in-development, supplements, nutraceuticals, or
food/drink with neuroprotective properties that warrant in-depth reviews by ADDF’s Aging and
Alzheimer’s Prevention Program, please contact [email protected]. To view our official
ratings, visit Cognitive Vitality’s Rating page.